Delving into the Latest Updates on RO-6799477 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization-

Inactive Organization

Hoffmann-La Roche, Inc.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

A randomized, double-blind, placebo-controlled study in two parts to investigate in Part 1 the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending dose of RO6799477 in healthy volunteers, and in Part 2 the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose of RO6799477 in patients with type 2 diabetes mellitus. - Research into the effects of RO6799477 during a longer period

Start Date19 Jun 2014

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

NCT02164266

/ CompletedPhase 1

A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477

This study is designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO6799477 following once daily oral administration for 2 weeks in healthy volunteers (Part 1) and in Type 2 diabetes patients (T2D) (Part 2). The anticipated time on study treatment is two weeks.

Start Date01 Jun 2014

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

NCT01893437

/ CompletedPhase 1

A Single-center, Randomized, Double-blind, Placebo-controlled, Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6799477 Following Oral Administration of Single Ascending Doses in Healthy Volunteers.

This single-center, randomized, double-blind, placebo-controlled, single dose study will investigate the safety, pharmacokinetics, pharmacodynamics of RO6799477 in healthy volunteers.

Start Date01 Jul 2013

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

100 Clinical Results associated with RO-6799477

Login to view more data

100 Translational Medicine associated with RO-6799477

Login to view more data

100 Patents (Medical) associated with RO-6799477

Login to view more data

100 Deals associated with RO-6799477

Login to view more data